In a statement earlier today DSP said that the deal fits with its strategy to “strengthen [its] business foundation as a first step in becoming a global corporation,” adding that the move will expand its US sales and marketing capability.
DSP’s efforts to bolster its US presence are timely given that it is preparing for the global launch of its new antipsychotic drug Lurasidone.
Company president Masayo Tada explained that: “Sepracor will become a centre of excellence for DSP in the US and will make a significant contribution to DSP.”
